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Summary 
 
Background  
Afatinib, an irreversible ErbB family blocker, improved progression-free survival (PFS) versus 
pemetrexed/cisplatin (LUX-Lung-3 [LL3]) or gemcitabine/cisplatin (LUX-Lung-6 [LL6]) in 
patients with lung adenocarcinoma harbouring epidermal growth factor receptor (EGFR) 
mutations. Overall survival (OS) was a pre-specified secondary endpoint.   
 
Methods 
Treatment-naïve patients with EGFR mutation-positive stage IIIB/IV lung adenocarcinoma 
(LL3=345; LL6=364) were randomised (2:1) to afatinib or chemotherapy, stratified by EGFR 
mutation (Del19/L858R/other) and race (LL3). Mature OS analyses, including pre-specified 
subgroup analyses, were planned in the intent-to-treat population after 209 (LL3) and 237 
(LL6) events. Individual patient data from these studies were also combined for post-hoc 
exploratory OS analyses. These ongoing (active, not recruiting) studies are registered with 
ClinicalTrials.gov: NCT00949650 (LL3), NCT01121393 (LL6). 
 
Findings 
In LL3 and LL6, median follow-up was 41 and 33 months, respectively, and 213 (62%) of 
345 patients and 246 (68%) of 364 patients had died. In each study, a trend towards OS 
improvement was observed with afatinib versus chemotherapy for all patients and those with 
tumours harbouring common EGFR mutations (Del19/L858R). OS was significantly 
improved with afatinib versus chemotherapy in patients with Del19 mutation-positive tumours 
in LL3 (33·3 months [95% CI 26·8–41·5] vs 21·1 months [16·3–30·7]; hazard ratio [HR] 0.54 
[95% CI 0·36–0·79; p=0·0015]) and LL6 (31·4 months [24·2–35·3] vs 18·4 months 
[14·6–25·6]; HR 0·64 [0·44–0·94; p=0·023]). In combined analyses, OS was improved with 
afatinib versus chemotherapy in patients with tumours harbouring common EGFR mutations 
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(27·3 months [24·2–31·0] vs 24·3 months [20·6–27·0]; HR 0·81 [0·66–0·99; p=0·037]); HRs 
were 0·59 (0·45–0·77; p=0·0001) for the Del19 subgroup and 1·25 (0·92–1·71; p=0·16) for 
the L858R subgroup. 
 
Interpretation 
LL3 and LL6 independently demonstrated significant improvements in OS with first-line 
afatinib versus chemotherapy in patients with lung adenocarcinoma harbouring EGFR Del19 
mutation; no difference was observed in the L858R mutation-positive subgroup. These 
findings suggest that patients with EGFR Del19 and L858R mutation-positive tumours are 
biologically distinct disease subgroups that should be analysed separately in future trials. 
 
Funding  
Boehringer Ingelheim. 
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Introduction 
 
Lung adenocarcinoma patients with tumours harbouring epidermal growth factor receptor 
(EGFR) mutations are highly responsive to treatment with EGFR tyrosine kinase inhibitors 
(TKIs) such as gefitinib, erlotinib, or afatinib.1 Seven randomised phase 3 studies conducted 
in this genetically-selected subset of lung cancer patients demonstrated superior 
progression-free survival (PFS) and response rate with gefitinib or erlotinib compared to 
platinum-based chemotherapy.2–8 However, overall survival (OS) benefit was not observed in 
these studies, irrespective of EGFR mutation type,8–15 presumed to be due to the fact that 
the majority of patients randomised to first-line chemotherapy were subsequently treated 
with EGFR TKIs. A meta-analysis of 13 randomised studies examining first-line gefitinib or 
erlotinib (monotherapy or combined with chemotherapy) compared to chemotherapy/placebo 
in patients with EGFR mutation-positive lung cancer concluded there was no difference in 
OS (hazard ratio [HR] 1·01 [95% confidence interval (CI) 0·87–1·18]) despite the 
overwhelming PFS advantage among those receiving EGFR TKIs (HR 0·43 [95% CI 
0·38–0·49; p<0·001]).16 
 
Afatinib, a second-generation irreversible TKI that inhibits signalling from all homodimers 
and heterodimers formed by ErbB receptor family members (EGFR, HER2, ErbB3, and 
ErbB4), has demonstrated clinical activity in EGFR TKI-naïve patients with EGFR 
mutation-positive lung adenocarcinoma.17–19 First-line afatinib versus standard 
chemotherapy was recently evaluated in two large, randomised phase 3 trials in 
treatment-naïve patients with EGFR mutation-positive advanced lung adenocarcinoma.18,19 
These two studies, designed to meet the regulatory requirements of different regions, were 
nearly identical in design with the exception of the platinum-based comparator regimen: 
pemetrexed/cisplatin in LUX-Lung-3 (LL3) and gemcitabine/cisplatin in LUX-Lung-6 (LL6). 
Both studies showed superior PFS (primary endpoint), objective response rate (ORR) and 
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patient-reported outcomes for patients receiving first-line afatinib.18–20 These studies also 
demonstrated differences in PFS with afatinib based on EGFR mutation type; PFS was most 
improved in patients with tumours harbouring exon 19 deletion (Del19) followed by the exon 
21 substitution (L858R) mutation.18,19  
 
Here we report mature OS results from the individual LL3 and LL6 studies. Additionally, in 
order to provide more accurate estimates of the overall treatment effect of afatinib in these 
patients, particularly in pre-specified subgroups, individual patient data from the LL3 and LL6 
studies were combined for an exploratory OS analysis. 
 
Methods 
 
Study design and endpoints  
Detailed study designs, inclusion/exclusion criteria, and methods of the primary analyses of 
LL3 and LL6 have been previously published.18,19 In brief, eligible patients were aged ≥18 
years, had previously untreated stage IIIB/IV lung adenocarcinoma (measurable disease 
according to Response Evaluation Criteria in Solid Tumors version 1.1) and confirmed EGFR 
mutations in the tumour (based on a validated test kit [Therascreen EGFR 29; Qiagen, 
Manchester, UK]), had an Eastern Cooperative Oncology Group (ECOG) performance status 
of 0 or 1, and a life expectancy of at least three months.  
 
Patients enrolled in LL3 (N=345; recruited globally) and LL6 (N=364; recruited in China, 
Korea, and Thailand) were randomised (2:1) to receive afatinib or chemotherapy, stratified 
by EGFR mutation type (Del19 vs L858R vs other ‘uncommon’ mutations) and race (Asian 
vs non-Asian; LL3 only); a block size of 3 was used within each of the strata. Randomisation 
was performed using a validated random number generating system at Boehringer 
Ingelheim, verified by a trial-independent statistician, and implemented centrally via an 
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Interactive Voice/Web Response System; individuals directly involved in the conduct and 
analysis of the trial did not have access to the randomisation schedule. Patients received 
either continuous oral afatinib (40 mg/day; Boehringer Ingelheim Pharma GmbH & Co. KG, 
Ingelheim, Germany) or up to six cycles of intravenous pemetrexed (500 mg/m2) plus 
cisplatin (75 mg/m2) once every 21 days in LL3 or gemcitabine (1000 mg/m2; day 1 and 8) 
plus cisplatin (75 mg/m2; day 1) every 21 days in LL6. Patients receiving afatinib were 
permitted to dose escalate to 50 mg/day after the first 21-day cycle if they did not experience 
treatment-related adverse events (AEs) greater than grade 1. Afatinib dose reduction by 
10-mg decrements down to 20 mg/day was allowed for treatment-related grade 3 or selected 
prolonged grade 2 AEs, as previously described.18,19 Dose reductions for patients receiving 
chemotherapy were in accordance with guidance provided in the current summary of product 
characteristics and institutional guidelines. 
 
In both studies, the primary endpoint was PFS, defined as time from randomisation to 
progression (as determined by independent review). Key secondary endpoints were ORR 
(complete response and partial response), disease control rate (ORR and stable disease), 
and OS; other secondary endpoints included patient-reported outcomes and safety. Tumour 
assessments were performed by computed tomography or magnetic resonance imaging 
every six weeks for the first 48 weeks and then every 12 weeks thereafter until disease 
progression or start of new anticancer therapy. AEs were categorised and graded using the 
National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0. After 
the last scheduled follow-up visit for the primary endpoint, patients were contacted every 2 
months to collect information on subsequent therapies and survival until patient death, loss 
to follow-up, or withdrawal of consent. 
 
Both studies were conducted in accordance with the Declaration of Helsinki and guidelines 
on Good Clinical Practice, and the protocols were approved by local ethics committees at 
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each participating center. Written informed consent was obtained for each patient. 
 
Statistical analyses 
Each study was powered (90%) at a two-sided 5% significance level to detect a PFS 
improvement from 7 months (combination chemotherapy) to 11 months (afatinib) after a 
minimum of 217 progression events by independent review, with estimated samples sizes of 
at least 330 patients for each study.18,19 Primary and key secondary endpoints were analysed 
following a hierarchical testing strategy to minimise the overall risk of type I error (5%). OS 
analyses were planned for two time points. The first OS analysis was concurrent with the 
primary PFS analysis; a Haybittle-Peto stopping boundary was used (p<0·0001) to preserve 
the overall 5% type I error. The second OS analysis was planned after 209 deaths in LL3 
and 237 deaths in LL6, when it was estimated that the data would be mature. LL3 and LL6 
were not purposefully designed with sufficient power to detect OS differences, given that 
none of the previous studies comparing first-line erlotinib or gefitinib to chemotherapy 
demonstrated OS benefits.8–15 Similar to the primary PFS analysis, pre-planned stratification 
by EGFR mutation type (Del19/L858R/other) and race (Asian vs non-Asian; LL3 only) was 
applied for the OS analysis. Pre-planned analyses of additional subgroups of special interest 
(gender, age, baseline ECOG performance status, EGFR mutation category [‘common’ vs 
‘uncommon’], and smoking history) were also defined. As these did not form part of the 
confirmatory analysis strategy, no adjustment for multiplicity was performed, and p values 
can be considered descriptive in nature. A post-hoc exploratory OS analysis based on the 
combined individual patient data from LL3 and LL6 was performed; heterogeneity was 
evaluated by testing the study-by-treatment interaction. All efficacy analyses were performed 
in an intent-to-treat manner, including all patients randomised to treatment. 
 
For each study, the main comparison of OS between treatment arms was performed using a 
stratified log-rank test adjusting for EGFR mutation type (LL3 and LL6) and race (LL3); the 
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combined OS analysis was adjusted for study (LL3/LL6) and EGFR mutation type. Cox 
proportional-hazard models were used to derive HRs and 95% CIs comparing the two 
treatment arms, and examining patient subgroups of interest. The proportional hazards 
assumption was checked via a test for proportionality21 along with visual checks of the 
log-cumulative hazard plots. Kaplan-Meier (KM) estimates were used to construct survival 
curves and calculate median OS. Median follow-up was calculated using the reverse KM 
method.22 Statistical analyses were performed with SAS (version 9.2). 
  
Role of the funding source 
Boehringer Ingelheim managed the clinical trial database. JC-HY, Y-LW, LVS, and the 
Boehringer Ingelheim study team analysed the data according to the statistical plan and 
decided upon exploratory analyses. JC-HY had full access to the study data and prepared 
the manuscript draft, and all authors participated in the manuscript development and made 
the final decision to submit the manuscript for publication. 
 
Results 
 
Patients 
Patients were randomised between August 2009 and February 2011 in LL3, and between 
April 2010 and November 2011 in LL6. 345 patients in LL3 and 364 patients in LL6 were 
randomly assigned to study treatment (figure 1); all randomised patients were included in the 
OS analysis. Patient baseline characteristics are listed in table 1. In both studies, the 
majority of patients were females (LL3: 224 [65%] of 345 patients; LL6: 238 [65%] of 364 
patients), never smokers (LL3: 236 [68%] of 345 patients; LL6: 280 [77%] of 364 patients), 
had stage IV disease (LL3: 308 [89%] of 345 patients; LL6: 342 [94%] of 364 patients), and 
had an ECOG performance status of 1 (LL3: 212 [61%] of 345 patients; LL6: 275 [76%] of 
364 patients). In the LL3 study, which recruited globally, 249 (72%) of 345 patients were 
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Asian. All patients enrolled in LL6 were Asian. The majority of patients in each study had 
tumours harbouring common EGFR mutations (Del19/L858R; LL3: 307 [89%] of 345 patients; 
LL6: 324 [89%] of 364 patients); approximately half of patients (LL3: 169 [49%] of 345 
patients; LL6: 186 [51%] of 364 patients) had EGFR Del19 mutation-positive tumours. This 
analysis focused on clinical outcomes in patients with tumours harbouring common EGFR 
mutations. As patients with lung adenocarcinoma harbouring uncommon EGFR mutations 
represent a heterogeneous population with variable responses to treatment, a dedicated 
manuscript is in development to detail the outcomes of these patients. 
 
At the data cutoff for this analysis (November 2013 for LL3 and December 2013 for LL6), the 
median (interquartile range [IQR]) duration of follow-up was 41 (IQR 35–44) months in LL3 
and 33 (IQR 31–37) months in LL6; 213 (62%) of 345 patients and 246 (68%) of 364 patients 
had died. As 21 (9%) of 230 patients in LL3 and 23 (10%) of 242 patients in LL6 were still 
receiving afatinib treatment at the cutoff, follow-up for OS and data on subsequent therapies 
are not final. 
 
Individual trial OS analyses 
In the overall populations, median OS was 28 months (afatinib: 95% CI 24·6–33·6; 
pemetrexed/cisplatin: 20·7–33·2) in each treatment arm in LL3 (HR 0·88 [95% CI 0·66–1·17; 
p=0·39]; figure 2A), and 23 months (afatinib: 20·4–27·3; gemcitabine/cisplatin: 18·0–25·6) in 
each treatment arm in LL6 (HR 0·93 [95% CI 0·72–1·22; p=0·61]; figure 2B). In patients with 
tumours harbouring common EGFR mutations (Del19 and L858R combined), median OS 
with afatinib and chemotherapy was 31·6 months (95% CI 26·7–35·3) and 28·2 months 
(20·6–32·3; HR 0·78 [95% CI 0·58–1·06; p=0·11]) in LL3, and 23·6 months (20·5–28·5) and 
23·5 months (17·8–25·4; HR 0·83 [95% CI 0·62–1·09; p=0·18]) in LL6 (figures 3A and 3B).  
 
In subgroup analyses examining EGFR mutation type in both LL3 and LL6, a significant 
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improvement with afatinib compared to chemotherapy was observed in patients with tumours 
harbouring the EGFR Del19 mutation (figure 3D). In LL3, median OS for these patients was 
33·3 months (95% CI 26·8–41·5) with afatinib versus 21·1 months (16·3–30·7) with 
chemotherapy (HR 0·54 [95% CI 0·36–0·79; p=0·0015]; figure 4A). In LL6, median OS for 
patients with EGFR Del19 mutation-positive tumours was 31·4 months (24·2–35·3) with 
afatinib versus 18·4 months (14·6–25·6) with chemotherapy (HR 0·64 [95% CI 0·44–0·94; 
p=0·023]; figure 4B). No significant differences were observed by treatment arm for patients 
with EGFR L858R mutation-positive disease in either LL3 (HR 1·30 [95% CI 0·80–2·11; 
p=0·29]; figure 4D) or LL6 (HR 1·22 [95% CI 0·81–1·83; p=0·34]; figure 4E). 
 
Patients with disease progression or intolerable AEs discontinued assigned study medication 
(first-line afatinib or chemotherapy) and received subsequent standard treatment at their 
physician’s discretion. In LL3, drug-related AEs leading to treatment discontinuation in >1 
patient included diarrhoea (three, 1%), paronychia (two, 1%) and interstitial lung disease 
(two, 1%) in 229 afatinib-treated patients, and fatigue (three, 3%) in 111 
pemetrexed/cisplatin-treated patients. Drug-related AEs leading to discontinuation in LL6 
included rash (five, 2%) in 239 afatinib-treated patients, and vomiting (16, 14%), nausea (11, 
10%), neutropenia (10, 9%), leukopenia (eight, 7%), AEs related to platelet and white blood 
cell count (five, 4%), anaemia (four, 4%), thrombocytopenia (four, 4%), fatigue (four, 4%), 
hepatic function abnormal (two, 2%), and renal failure (two, 2%) in 113 
gemcitabine/cisplatin-treated patients. Complete safety analyses, including incidence of AEs, 
dose reductions, discontinuations and fatalities, in LL3 and LL6 have been previously 
reported.18,19 
 
Subsequent treatment regimens received are summarised by EGFR mutation type for each 
study in table 2. Subsequent treatment with chemotherapy or an EGFR TKI following 
first-line therapy was balanced across treatment arms within each study. Among patients 
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who discontinued study medication in LL3, 78 (75%) of 104 chemotherapy-treated patients 
with tumours harbouring common EGFR mutations subsequently received an EGFR TKI, 
and 131 (71%) of 184 afatinib-treated patients received subsequent chemotherapy. Among 
patients who discontinued study medication in LL6, 61 (56%) of 108 chemotherapy-treated 
patients and 114 (59%) of 194 afatinib-treated patients received subsequent EGFR TKI 
therapy or chemotherapy, respectively. In addition, there were no differences in the 
proportion of patients receiving subsequent treatment with chemotherapy or an EGFR TKI 
following first-line therapy by EGFR mutation type (table 2). Of note, patients randomised to 
first-line chemotherapy typically received erlotinib or gefitinib as later-line EGFR TKI 
treatment because afatinib was not clinically available at the time. 
 
Exploratory combined OS analysis  
Individual patient data from LL3 and LL6 were combined for the afatinib (n=472) and 
chemotherapy (n=237) treatment arms for exploratory analyses. As the two studies had very 
similar designs and were conducted simultaneously, heterogeneity in this combined analysis 
was minimal (p=0·92). Median OS in the combined overall population was 25·8 months 
(95% CI 23·1–29·3) with afatinib and 24·5 months (21·1–28·1) with chemotherapy (HR 0·91 
[95% CI 0·75–1·11; p=0·37]; figure 2C). Among patients with tumours harbouring common 
EGFR mutations (afatinib, n=419; chemotherapy, n=212), OS was significantly improved 
with afatinib compared to chemotherapy (median 27·3 months [24·2–31·0] vs 24·3 months 
[20·6–27·0]; HR 0·81 [95% CI 0·66–0·99; p=0·037]; figure 3C). Consistent with individual 
study findings, subgroup analyses indicated that the OS benefit of afatinib was driven 
primarily by patients with EGFR Del19 mutation-positive tumours (figure 3D). In these 
patients, median OS was 31·7 months (28·1–35·1) versus 20·7 months (16·3–25·6; HR 0·59 
[95% CI 0·45–0·77; p=0·0001]; figure 4C), while in patients with EGFR L858R 
mutation-positive tumours, median OS was 22·1 months (19·6–25·4) versus 26·9 months 
(23·2–31·7; HR 1·25 [95% CI 0·92–1·71; p=0·16]; figure 4F). Of note, HRs favoured afatinib 
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for all but two of the subgroups analysed (figure 3D). In the subgroup of non-Asian patients 
with tumours harbouring common EGFR mutations (n=83) in LL3, median OS was 28·1 
months (22·1–not estimable) with afatinib versus 20·7 months (16·7–33·5) with 
chemotherapy (HR 0·68, [95% CI 0·39–1·20; p=0·18]), with a significant improvement in 
non-Asian patients harbouring EGFR Del19 mutation-positive tumours (n=46; 33·6 months 
[24·6–not estimable] vs 20·0 months [11·2–33·5]; HR 0·45 [95% CI 0·21–0·95; p=0·03]). 
 
In addition to analyses of subsequent treatment received in the individual LL3 and LL6 
studies described above, exploratory combined analyses among LL3 and LL6 patients 
treated in countries with or without a universal healthcare reimbursement policy were 
conducted to examine whether regional and systematic access to subsequent therapies had 
an influence on OS in these studies. These results are presented in table S1 and figure S1.  
 
Discussion 
 
Randomised studies comparing first-line EGFR TKIs with standard chemotherapies suggest 
that patients with lung adenocarcinoma harbouring EGFR mutations benefit from first-line 
EGFR TKI treatment, with improved response, PFS, and quality of life, although no 
improvements in OS have been reported.2–8,18,19 To our knowledge, these two independent 
phase 3 studies have demonstrated for the first time that first-line afatinib significantly 
improved OS compared to chemotherapy in patients with lung adenocarcinoma harbouring 
the EGFR Del19 mutation; no difference was observed in patients with L858R 
mutation-positive disease. Importantly, while the majority of patients in LL3 and the entire 
population of LL6 were Asian, a significant improvement in OS with afatinib in the Del19 
subgroup was also observed in the smaller subpopulation of non-Asian patients in LL3, 
supporting the applicability of the findings to all patients with EGFR mutation-positive 
disease, regardless of race. The recommendation to use EGFR TKIs as first-line therapy in 
15 
 
patients with EGFR mutation-positive disease was based solely on PFS improvement over 
chemotherapy. 2–8,18,19 Based on this report, the evidence to recommend afatinib as first-line 
therapy in patients with EGFR Del19 mutation-positive disease now includes OS benefit.  
 
EGFR Del19 and L858R mutations comprise up to 90% of all EGFR mutation-positive lung 
adenocarcinoma23 and are strongly associated with response to EGFR TKIs.24 In 
retrospective analyses, patients with EGFR Del19 mutation-positive tumours consistently 
demonstrated greater response rates, time to progression, and survival with erlotinib and 
gefitinib compared to L858R mutation-positive disease.25–27 In a large prospective registry of 
patients treated with erlotinib, multivariate analysis showed that EGFR L858R mutation was 
associated with poorer PFS and OS compared with Del19 mutation.23 Further, in a 
meta-analysis of six randomised studies comparing EGFR TKIs to chemotherapy in patients 
with EGFR mutation-positive lung adenocarcinoma, Del19 mutation was associated with 
significantly greater benefit from EGFR TKI therapy compared to chemotherapy than L858R 
mutation (p=0·001).28 The etiology of this pervasive difference in outcomes on EGFR TKIs 
by EGFR mutation subtype is not known. Previously reported results of the LL3 and LL6 
studies demonstrated PFS benefit with afatinib versus chemotherapy in patients with EGFR 
Del19 mutation-positive tumours and those with the L858R mutation, though consistent with 
prior literature greater benefit was observed in Del19 mutation-positive disease.18,19 Within 
this landscape, our analysis now suggests that afatinib significantly improves OS compared 
to chemotherapy among patients with EGFR Del19 mutation-positive tumours that is not 
observed in L858R mutation-positive disease, where clinical benefit of afatinib over 
chemotherapy was demonstrated in terms of PFS and ORR.18,19 Although subgroups and 
their analyses were pre-planned, no p value adjustment for multiplicity was performed, thus 
increasing the chance of a false positive finding. However, for the EGFR Del19 mutation 
subgroup, statistical evidence was considerably stronger than p<0·05, particularly for LL3 
(p=0·0015); this coupled with the replication of the result across two independent trials is 
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strong evidence that the effect is genuine. 
 
Previous reports of reversible EGFR TKIs erlotinib and gefitinib have not demonstrated an 
OS benefit compared to chemotherapy in overall study populations or by EGFR mutation 
type.8–15 As EGFR TKI sensitivity among EGFR-mutant tumours is not adversely affected by 
chemotherapy pretreatment,23 any OS benefit of first-line EGFR TKIs in these studies was 
thought to be offset by subsequent treatment with second-line EGFR TKIs following 
progression on chemotherapy. Since afatinib was not clinically available at the time of the 
LL3 and LL6 studies, very few patients received afatinib as later-line EGFR TKI treatment; 
the majority received erlotinib or gefitinib after chemotherapy. The clinically meaningful 
difference in median OS observed with afatinib compared to chemotherapy in patients with 
EGFR Del19 mutation-positive tumours in both studies may be attributed to mechanistic 
differences between the irreversible ErbB family blocker afatinib and first-generation 
reversible EGFR TKIs. Further, preclinical studies have shown that EGFR Del19 and L858R 
mutants have distinct biological properties that may impact response to different EGFR 
TKIs.29,30 
 
In LL3, the proportion of patients receiving subsequent therapies following study 
discontinuation was consistent with reports of similar randomised trials.5,6,9,11,12 In LL6, which 
had less follow-up at the time of data cutoff, the proportion of patients receiving subsequent 
therapies was lower in both arms, potentially reflecting reduced access to treatments in 
certain countries with different healthcare systems. It is also important to note that the group 
of patients who did not receive subsequent treatments in both LL3 and LL6 included those 
who experienced early death, withdrew consent, or were lost to follow-up. In exploratory 
combined analyses among patients in LL3 and LL6 treated in countries with or without a 
universal healthcare reimbursement policy, more patients received subsequent therapy in 
countries with a universal reimbursement policy than countries without a universal policy. 
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Further, greater access to subsequent therapy was associated with improved median OS in 
both treatment groups, yet the OS benefit with afatinib over chemotherapy was maintained. 
In addition, no differences were observed in the proportions of patients receiving subsequent 
therapies in the EGFR Del19 and L858R subgroups within each study, indicating that the OS 
benefit seen with afatinib in Del19 mutation-positive disease is unlikely attributable to 
follow-up treatment. 
 
The LL3 control arm of pemetrexed/cisplatin is one of the most commonly used regimens for 
patients with nonsquamous non-small cell lung cancer.31 At the time of LL3 initiation, 
pemetrexed maintenance following initial pemetrexed/cisplatin treatment was not standard of 
care. Recent results from the PARAMOUNT study showed a statistically significant 
improvement in OS with maintenance pemetrexed therapy compared to placebo; however, 
only a 2-month difference in OS versus placebo was observed.32 Bevacizumab was also 
evaluated in combination with pemetrexed for maintenance therapy following 
pemetrexed/cisplatin induction therapy in the phase 3 AVAPERL trial.33 Although the addition 
of bevacizumab to the combination therapy improved PFS, a significant benefit in OS was 
not observed. Thus, it is unlikely that the 1-year OS benefit observed with afatinib versus 
chemotherapy in the current studies would have been impacted by the addition of 
pemetrexed and/or bevacizumab maintenance therapy to the chemotherapy arm.    
 
In summary, LL3 and LL6 independently demonstrate that afatinib provided significant 
improvements in OS compared to platinum-doublet chemotherapy in patients with EGFR 
Del19 mutation-positive lung adenocarcinoma, but not the L858R mutation-positive 
subgroup. These are the only two studies to date that reveal an OS advantage for EGFR 
Del19 mutation-positive disease treated with a first-line EGFR TKI. Further, these findings 
suggest that patients with lung adenocarcinoma harbouring EGFR Del19 and L858R 
mutations should be stratified and analysed separately in future clinical trials. 
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Research in context 
Systematic Review 
A systematic review of the literature using PubMed to identify phase III, randomised trials 
evaluating first-line EGFR TKI therapy versus standard platinum-based chemotherapy 
regimens in treatment-naïve patients with EGFR mutation-positive advanced lung 
adenocarcinoma identified seven trials conducted with reversible EGFR TKIs gefitinib (four 
trials2–4,8–12,15) and erlotinib (three trials5–7,13,14), and two trials conducted with the 
second-generation irreversible TKI afatinib (LL3 and LL618,19). In each of these studies, 
significant improvements in PFS and response rate were observed with EGFR TKI therapy 
versus chemotherapy.2–8,18,19 None of the studies were designed to detect a difference in OS 
in the overall population or in EGFR Del19 or L858R mutation subgroups. In this context, OS 
benefit over chemotherapy was not observed in the gefitinib or erlotinib studies.8–15 Only the 
IPASS, NEJ002 and EURTAC trials examined OS with reversible EGFR TKIs specifically in 
EGFR Del19 or L858R mutation subgroups; no differences in OS were observed.9–11,13 
 
Interpretation 
LL3 and LL6 previously corroborated the findings of other randomised trials in this setting 
with regards to our understanding of EGFR mutation-positive lung adenocarcinoma and 
response to EGFR TKIs based on assessments of tumour response and PFS.18,19 To our 
knowledge, both LL3 and LL6 have independently demonstrated for the first time a survival 
benefit in patients with lung adenocarcinoma harbouring the EGFR Del19 mutation receiving 
first-line afatinib versus platinum-doublet chemotherapy, whereas no difference was 
observed in L858R mutation-positive disease. This finding suggests that among standard 
first-line EGFR TKIs, afatinib should be the preferred option for patients with EGFR Del19 
mutation-positive lung adenocarcinoma. Of note, the difference in outcomes for patients with 
EGFR Del19 and L858R mutation-positive disease suggests that these populations should 
be studied separately in future trials. 
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Tables 
Table 1: Patient demographics and baseline characteristics 
 LUX-Lung 3 LUX-Lung 6 Combined analysis 
 
Afatinib 
(n=230) 
Cisplatin/pemetrexed 
(n=115) 
Afatinib 
(n=242) 
Cisplatin/gemcitabine 
(n=122) 
Afatinib 
(n=472) 
Chemotherapy 
(n=237) 
Gender, n (%)       
Male 83 (36·1) 38 (33·0) 87 (36·0) 39 (32·0) 170 (36·0) 77 (32·5) 
Female 147 (63·9) 77 (67·0) 155 (64·0) 83 (68·0) 302 (64·0) 160 (67·5) 
Median (range) age, years 62 (28–86) 61 (31–83) 58 (29–79) 58 (27–76) 60 (28–86) 59 (27–83) 
Race, n (%)       
Asian 166 (72·2) 83 (72·2) 242 (100·0) 122 (100·0) 408 (86·4) 205 (86·5) 
Non-Asian 64 (27·8) 32 (27·8) 0 0 64 (13·6) 32 (13·5) 
Adenocarcinoma stage, n (%)       
IIIB with pleural effusion 20 (8·7) 17 (14·8) 16 (6·6) 6 (4·9) 36 (7·6) 23 (9·7) 
IV 210 (91·3) 98 (85·2) 226 (93·4) 116 (95·1) 436 (92·4) 214 (90·3) 
Baseline ECOG PS       
0 92 (40·0) 41 (35·7) 48 (19·8) 41 (33·6) 140 (29·7) 82 (34·6) 
1 138 (60·0) 74 (64·3)* 194 (80·2) 81 (66·4) 332 (70·3) 155 (65·4)* 
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EGFR mutation, n (%)       
Common mutations 203 (88·3) 104 (90·4) 216 (89·3) 108 (88·5) 419 (88·8) 212 (89·5) 
Exon 19 deletion 112 (48·7) 57 (49·6) 124 (51·2) 62 (50·8) 236 (50·0) 119 (50·2) 
L858R 91 (39·6) 47 (40·9) 92 (38·0) 46 (37·7) 183 (38·8) 93 (39·2) 
Uncommon mutations† 27 (11·7)‡ 11 (9·6) 26 (10·7) 14 (11·5) 53 (11·2)‡ 25 (10·5) 
Smoking status, n (%)       
Never 155 (67·4) 81 (70·4) 181 (74·8) 99 (81·1) 336 (71·2) 180 (75·9) 
Former 70 (30·4) 32 (27·8) 44 (18·2) 13 (10·7) 114 (24·2) 45 (19·0) 
Current 5 (2·2) 2 (1·7) 17 (7·0) 10 (8·2) 22 (4·7) 12 (5·1) 
ECOG PS=Eastern Cooperative Oncology Group performance status. EGFR=epidermal growth factor receptor. *Includes one patient with an ECOG PS of 2. 
†Including T790M, exon 20 insertions, G719X, S768I, and L861Q, alone or as complex mutations in two or more exons. ‡Includes one patient with wild-type 
EGFR who was randomised in error.
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Table 2: Treatment beyond first-line therapy in patients with common EGFR mutations 
(Del19/L858R) in LL3 and LL6 
 Del19 L858R 
LUX-Lung 3 
Afatinib 
(n=112) 
Cisplatin/ 
pemetrexed 
(n=57) 
Afatinib 
(n=91) 
Cisplatin/ 
pemetrexed 
(n=47) 
Discontinued study 
treatment, n 
100 57 84 47 
Received subsequent 
systemic therapy, n (%)* 
76 (76·0) 49 (86·0) 68 (81·0) 39 (83·0) 
Chemotherapy 69 (69·0) 29 (50·9) 62 (73·8) 20 (42·6) 
EGFR TKI therapy 41 (41·0) 43 (75·4) 40 (47·6) 35 (74·5) 
Erlotinib  32 (32·0) 27 (47·4) 29 (34·5) 19 (40·4) 
Gefitinib 14 (14·0) 26 (45·6) 14 (16·7) 18 (38·3) 
Afatinib 1 (1·0) 6 (10·5) 1 (1·2) 1 (2·1) 
AZD9291 1 (1·0) 1 (1·8) 1 (1·2) 0 (0) 
Dacomitinib 0 (0) 0 (0) 0 (0) 1 (2·1) 
EGFR TKI combinations 2 (2·0) 8 (14·0) 3 (3·6) 3 (6·4) 
Other 2 (2·0) 1 (1·8) 3 (3·6) 1 (2·1) 
Radiotherapy 18 (18·0) 13 (22·8) 14 (16·7) 8 (17·0) 
LUX-Lung 6 
Afatinib 
(n=124) 
Cisplatin/ 
gemcitabine  
(n=62) 
Afatinib 
(n=92) 
Cisplatin/ 
gemcitabine 
(n=46) 
Discontinued study 
treatment, n 
110 62 84 46 
Received subsequent 
systemic therapy, n (%)* 
79 (71·8) 39 (62·9) 44 (52·4) 31 (67·4) 
Chemotherapy 72 (65·5) 16 (25·8) 42 (50·0) 13 (28·3) 
EGFR TKI therapy 36 (32·7) 33 (53·2) 14 (16·7) 28 (60·9) 
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Gefitinib  15 (13·6) 19 (30·6) 4 (4·8) 20 (43·5) 
Erlotinib 15 (13·6) 11 (17·7) 6 (7·1) 11 (23·9) 
Icotinib 8 (7·3) 3 (4·8) 3 (3·6) 0 (0) 
EGFR TKI combinations 4 (3·6) 2 (3·2) 1 (1·2) 1 (2·2) 
Other 2 (1·8) 2 (3·2) 1 (1·2) 2 (4·3) 
Radiotherapy 4 (3·6) 0 (0) 0 (0) 0 (0) 
EGFR=epidermal growth factor receptor. LL3=LUX-Lung 3. LL6=LUX-Lung 6. TKI=tyrosine kinase 
inhibitor. *Percentages based on the number of patients who discontinued treatment. Collection of 
data on subsequent therapies is still ongoing. 
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Figures 
 
Figure 1: Patient disposition 
 
 
AE=adverse event. EGFR=epidermal growth factor receptor. LL3=LUX-Lung 3. LL6=LUX-Lung 6. 
OS=overall survival. *Reasons for exclusion prior to randomisation in LL3 included: did not meet 
inclusion criteria (n=59), withdrew consent (n=24), AEs (n=5), lost to follow up (n=5), and other reason 
(n=15); in LL6 reasons included did not meet inclusion criteria (n=51), withdrew consent (n=38), AEs 
(n=1), and other reason (n=17). †OS analyses included all patients randomised to receive study 
medication. ‡Includes one patient with wild-type EGFR randomised in error. §One patient in LL3 and 
three patients in LL6 did not receive afatinib treatment; four patients in LL3 and nine patients in LL6 
did not receive chemotherapy. #Cisplatin/pemetrexed in LL3; cisplatin/gemcitabine in LL6. 
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Figure 2: Kaplan-Meier curves of overall survival in the overall populations of LL3 (A), 
LL6 (B), and the combined analysis (C) 
 
 
Chemo=chemotherapy. CI=confidence interval. Gem/cis=gemcitabine/cisplatin. LL3=LUX-Lung 3. 
LL6=LUX-Lung 6. OS=overall survival. Pem/cis=pemetrexed/cisplatin.
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Figure 3: Kaplan-Meier curves (A–C) and subgroup analyses (D) of overall survival in 
patients with common EGFR mutations (Del19/L858R combined) in LL3, LL6, and the 
combined analysis 
 
 
Chemo=chemotherapy. CI=confidence interval. ECOG=Eastern Cooperative Oncology Group. 
EGFR=epidermal growth factor receptor. Gem/cis=gemcitabine/cisplatin. LL3=LUX-Lung 3. 
LL6=LUX-Lung 6. OS=overall survival. Pem/cis=pemetrexed/cisplatin.
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Figure 4: Kaplan-Meier curves of overall survival in Del19 patients (A–C) and L858R 
patients (D–F) in LL3, LL6, and the combined analysis  
 
 
Chemo=chemotherapy. CI=confidence interval. Gem/cis=gemcitabine/cisplatin. LL3=LUX-Lung 3. 
LL6=LUX-Lung 6. NE=not estimable. OS=overall survival. Pem/cis=pemetrexed/cisplatin. 
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Figure S1: Exploratory analysis of overall survival in patients with common EGFR 
mutations (Del19/L858R combined) (A), Del19 patients only (B) and L858R patients 
only (C) in countries with or without universal reimbursement policies for EGFR TKI 
therapies* In those patients with greater access to subsequent therapy, improved median 
OS was observed in both the afatinib and chemotherapy treatment groups, with an OS 
benefit observed with afatinib versus chemotherapy. For example, in Japan, all patients 
assigned to chemotherapy received a subsequent EGFR TKI after progression. Among 
Japanese patients, the OS benefit of afatinib compared to chemotherapy was more 
pronounced in patients with tumours harbouring EGFR Del19 mutation (HR 0·34) and those 
with common mutations (HR 0·57) compared to the overall study population. 
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Chemo=chemotherapy. CI=confidence interval. EGFR=epidermal growth factor receptor. NE=not 
estimable. OS=overall survival. TKI=tyrosine kinase inhibitor. *Determined by presence or absence of 
a national reimbursement policy in effect throughout the period of trial conduct. †Main countries 
contributing: Japan, Taiwan, Korea, Germany, France, Australia, UK, Belgium, Ireland. ‡Main 
countries contributing: China, Thailand, Russia, the Philippines, Malaysia.
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Table S1: Subsequent treatments in patients with common EGFR mutations 
(Del19/L858R combined) in countries with or without universal reimbursement 
policies for EGFR TKI therapies* More patients received subsequent therapy in countries 
with a universal reimbursement policy than countries without a universal policy. 
 
With universal  
reimbursement policies† 
Without universal 
reimbursement policies‡ 
 
Afatinib 
(n=144) 
Chemotherapy 
(n=75) 
Afatinib 
(n=275) 
Chemotherapy 
(n=137) 
Discontinued study 
treatment, n 
127 75 251 137 
Received subsequent 
systemic therapy, n (%)§ 
112 (88·2) 69 (92·0) 155 (61·8) 89 (65·0) 
Chemotherapy 103 (81·1) 35 (46·7) 142 (56·6) 43 (31·4) 
EGFR TKI therapy# 76 (59·8) 68 (90·7) 55 (21·9) 71 (51·8) 
Other 5 (3·9) 2 (2·7) 3 (1·2) 4 (2·9) 
Radiotherapy 27 (21·3) 18 (24·0) 9 (3·6) 3 (2·2) 
EGFR=epidermal growth factor receptor. TKI=tyrosine kinase inhibitor. *Determined by presence or 
absence of a national reimbursement policy in effect throughout the period of trial conduct. †Main 
countries contributing: Japan, Taiwan, Korea, Germany, France, Australia, UK, Belgium, Ireland. 
‡Main countries contributing: China, Thailand, Russia, the Philippines, Malaysia. §Percentages based 
on the number of patients who discontinued treatment. Collection of data on subsequent therapies is 
still ongoing. #Including EGFR TKI-containing combination therapy. 
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Table S2: LUX-Lung 3 disposition of patients by country and site of enrollment 
 
Country Centre Investigator 
Number of randomised 
patients 
Thailand 3701 Geater 33 
Taiwan 3602 Tsai 15 
Taiwan 3601 Yang 12 
Germany 4305 Schuler 10 
Japan 3221 Terufumi 10 
Taiwan 3606 Su 10 
Russia 5504 Orlov 10 
Taiwan 3607 Lin 9 
Korea 3304 Lee 9 
Thailand 3704 Sirisinha 9 
Japan 3202 Takahashi 8 
Japan 3214 Yoshioka 8 
Philippines 3503 Parra 8 
Japan 3205 Nakagawa 7 
Japan 3216 Tanaka 7 
Japan 3204 Hida 6 
Japan 3209 Kiura 6 
Japan 3207 Seto 6 
Taiwan 3603 Ho 6 
Taiwan 3605 Hsia 6 
Korea 3301 Kim 6 
Hong Kong 3102 Lee 5 
Japan 3203 Goto 5 
Philippines 3501 Tudtud 5 
Australia 2711 Boyer 4 
France 4207 Bennouna 4 
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Japan 3211 Kasahara 4 
Japan 3217 Saka 4 
Japan 3206 Takeda 4 
Malaysia 3403 Chong−Kin 4 
Peru 2503 Lopez 4 
Russia 5505 Gorbunova 4 
Philippines 3502 Caguioa 4 
United Kingdom 4807 Shah 4 
Belgium 4105 Surmont 3 
France 4215 Paganin 3 
Ireland 4401 O’Byrne 3 
Japan 3219 Katakami 3 
Japan 3220 Nogami 3 
Malaysia 3402 Muttalif 3 
Russia 5506 Khasanov 3 
Korea 3303 Lee 3 
Thailand 3702 Thongprasert 3 
Australia 2707 Hazel 2 
Australia 2701 Pavlakis 2 
Belgium 4103 Ninane 2 
Germany 4306 Dickgreber 2 
Germany 4310 Sebastian 2 
France 4202 Sibilot 2 
Malaysia 3401 Ismail 2 
Taiwan 3608 Huang 2 
Chile 2303 Gonzalez 2 
Chile 2302 Ruiz 2 
Korea 3305 Joo Min 2 
Ukraine 5601 Bondarenko 2 
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Ukraine 5604 Vinnnik 2 
Austria 5101 Burghuber 1 
Australia 2703 Hughes 1 
Australia 2706 McLachlan 1 
Australia 2702 Parente 1 
Belgium 4102 Bosquee 1 
Belgium 4101 De Greve 1 
Belgium 4107 Vansteenkiste 1 
Brazil 2202 Barrios 1 
Canada 2903 Hirsh 1 
Germany 4308 Griesinger 1 
Germany 4311 Wiewrodt 1 
France 4210 Daniel 1 
France 4201 Perol 1 
France 4204 Zalcman 1 
Hungary 5302 Papai−Szekely 1 
Hong Kong 3101 Mok 1 
Japan 3218 Atagi 1 
Japan 3215 Oizumi 1 
Peru 2505 Lozada 1 
Peru 2501 Sanchez 1 
Argentina 2112 Carraro 1 
Argentina 2110 Fein 1 
Argentina 2101 Lerzo 1 
Taiwan 3604 Chang 1 
Taiwan 3609 Tsai 1 
Chile 2301 Diaz 1 
Russia 5503 Moiseyenko 1 
Russia 5507 Ragulin 1 
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Romania 5402 Cebotaru 1 
Romania 5401 Lungulescu 1 
Korea 3302 Kim 1 
United Kingdom 4806 Collinson 1 
United Kingdom 4803 Middleton 1 
United Kingdom 4801 Popat 1 
United Kingdom 4808 Toy 1 
United States 2606 Chandrasekaran 1 
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Table S3: LUX-Lung 6 disposition of patients by country and site of enrollment 
 
Country Centre Investigator 
Number of randomised 
patients 
Peoples Republic of China 8601 Wu 41 
Thailand 6601 Geater 24 
Peoples Republic of China 8603 Zhou 19 
Peoples Republic of China 8619 Hu 18 
Peoples Republic of China 8611 Feng 17 
Peoples Republic of China 8602 Lu 16 
Peoples Republic of China 8628 Huang 15 
Peoples Republic of China 8615 Li 14 
Peoples Republic of China 8617 Hou 14 
Peoples Republic of China 8629 Shi 14 
Peoples Republic of China 8613 Liu 13 
Peoples Republic of China 8614 Liu 13 
Peoples Republic of China 8604 Bai 12 
Peoples Republic of China 8621 Liang 12 
Peoples Republic of China 8622 Huang 12 
Peoples Republic of China 8608 Liu 10 
Peoples Republic of China 8624 Zhang 9 
Peoples Republic of China 8607 Wang 8 
Peoples Republic of China 8610 Qin 8 
Peoples Republic of China 8620 Luo 8 
Peoples Republic of China 8626 Zhu 7 
Peoples Republic of China 8630 Chen 7 
Peoples Republic of China 8632 Zhu 7 
Peoples Republic of China 8605 Li 6 
Peoples Republic of China 8616 Yu 6 
Peoples Republic of China 8618 Luo 6 
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Peoples Republic of China 8623 Song 6 
Korea 8201 Lee 5 
Korea 8205 Lee 5 
Peoples Republic of China 8609 Wang 5 
Peoples Republic of China 8631 Jianxing 3 
Korea 8203 Jang 2 
Korea 8202 Lee 1 
Peoples Republic of China 8627 Xiu 1 
 
 
 
 
